{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Direct+Acting+Antivirals", "query": { "intervention": "Direct Acting Antivirals" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 78, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Direct+Acting+Antivirals&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-22T18:20:40.471Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01851330", "title": "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C Virus" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 647, "start_date": "2013-05", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-22T18:20:40.471Z", "location_count": 52, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01851330" }, { "nct_id": "NCT01525628", "title": "Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "midazolam", "type": "DRUG" }, { "name": "BI 201335", "type": "DRUG" }, { "name": "tenofovir", "type": "DRUG" }, { "name": "caffeine", "type": "DRUG" }, { "name": "tolbutamide", "type": "DRUG" }, { "name": "pegylated interferon", "type": "DRUG" }, { "name": "BI 207127", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 72, "start_date": "2012-04", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2016-06-10", "last_synced_at": "2026-09-22T18:20:40.471Z", "location_count": 5, "location_summary": "La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Marlton", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01525628" }, { "nct_id": "NCT02639247", "title": "Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "SOF/VEL/VOX", "type": "DRUG" }, { "name": "SOF/VEL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2015-12-23", "completion_date": "2017-01-18", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-09-22T18:20:40.471Z", "location_count": 43, "location_summary": "Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Rialto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02639247" }, { "nct_id": "NCT01441180", "title": "GS-7977 With Ribavirin for Hepatitis C (SPARE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "GS7977", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2011-09", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2014-09-26", "last_synced_at": "2026-09-22T18:20:40.471Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01441180" }, { "nct_id": "NCT02607800", "title": "Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "SOF/VEL/VOX", "type": "DRUG" }, { "name": "SOF/VEL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 943, "start_date": "2015-11-16", "completion_date": "2017-01-11", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-09-22T18:20:40.471Z", "location_count": 47, "location_summary": "Long Beach, California • Los Angeles, California • Palo Alto, California + 44 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Rialto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02607800" }, { "nct_id": "NCT01701401", "title": "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C Virus" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 870, "start_date": "2012-09", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-22T18:20:40.471Z", "location_count": 53, "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01701401" }, { "nct_id": "NCT01805882", "title": "Combination Therapy for Chronic Hepatitis C Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "Ledipasvir", "type": "DRUG" }, { "name": "GS-9669", "type": "DRUG" }, { "name": "GS-9451", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2013-01", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-06-08", "last_synced_at": "2026-09-22T18:20:40.471Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01805882" }, { "nct_id": "NCT01726517", "title": "Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Virus" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2012-10", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-22T18:20:40.471Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01726517" }, { "nct_id": "NCT02743897", "title": "Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "End Stage Renal Disease" ], "interventions": [ { "name": "Zepatier", "type": "DRUG" }, { "name": "Mavyret", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "30 Years to 70 Years" }, "enrollment_count": 62, "start_date": "2016-05-01", "completion_date": "2022-12", "has_results": true, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-09-22T18:20:40.471Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02743897" }, { "nct_id": "NCT02533934", "title": "Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV", "Hepatitis C", "Cirrhosis" ], "interventions": [ { "name": "Harvoni", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2016-08", "completion_date": "2019-12-31", "has_results": true, "last_update_posted_date": "2021-02-02", "last_synced_at": "2026-09-22T18:20:40.471Z", "location_count": 8, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02533934" } ] }